Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10541320 | 0.89 | ALDH1A1 (0.70) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL7491797 | 0.87 | ALDH1A1 (0.73) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL3406144 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL22382437 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL4497059 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL2336351 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL10390221 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| Dinitrochlorobenzene SCHEMBL27642052 | 0.83 | SMN1; SMN2 (0.61) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL1569717 | 0.83 | SMN1; SMN2 (0.82) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT | |
| SCHEMBL5666032 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1HPGDHSP90AA1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003060078-A9 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | ALDH1A1 2884/4885HPGD 482/4885HSP90AA1 1586/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | ALDH1A1 2884/4885HPGD 482/4885HSP90AA1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.